Dab2 is pivotal for endothelial cell migration by mediating VEGF expression in cancer cells

被引:22
作者
Cheong, Seong-Moon [1 ]
Choi, Hyemin [1 ]
Hong, Bok Si [1 ]
Gho, Yong Song [1 ]
Han, Jin-Kwan [1 ]
机构
[1] Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea
关键词
Dab2; VEGF; TGF-beta; HUVEC; Angiogenesis; Cancer; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; EMBRYONIC ANGIOGENESIS; EPITHELIAL-CELLS; IN-VITRO; VASCULOGENESIS; DISABLED-2; DOC-2/DAB2;
D O I
10.1016/j.yexcr.2012.01.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Although angiogenesis is crucial for tumor growth and metastasis, the molecular mechanisms controlling this process are not clearly understood. Here, we explore the role of Dab2 in tumor angiogenesis. We found that Dab2 is expressed in several cancer cells, including A549 lung cancer cells, but it is hardly detectable in SW480 colon cancer cells. Migration and Erk phosphorylation were enhanced in human umbilical vein endothelial cells (HUVECs) treated with the conditioned medium obtained from Dab2-overexpressing SW480 stable cells. In addition, vascular endothelial growth factor (VEGF) protein was strongly detected in conditioned medium derived from Dab2-overexpressing SW480 cells, and Erk phosphorylation enhanced by Dab2(+) CM was restored by VEGF inhibition. Moreover, Dab2 depletion in A549 cells led to a decrease in HUVEC migration and Erk phosphorylation. Furthermore, we show that Dab2 is required for the TGF beta-induced gene expression of angiogenic factors such as VEGF and FGF2. Taken together, these results suggest that Dab2, which is expressed in cancer cells, is pivotal for endothelial cell migration by affecting VEGF expression. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:550 / 557
页数:8
相关论文
共 39 条
[1]
Benckert C, 2003, CANCER RES, V63, P1083
[2]
BREIER G, 1992, DEVELOPMENT, V114, P521
[3]
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[4]
Xenopus Dab2 is required for embryonic angiogenesis [J].
Cheong, Seong-Moon ;
Choi, Sun-Cheol ;
Han, Jin-Kwan .
BMC DEVELOPMENTAL BIOLOGY, 2006, 6
[5]
DICKSON MC, 1995, DEVELOPMENT, V121, P1845
[6]
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia [J].
Enholm, B ;
Paavonen, K ;
Ristimaki, A ;
Kumar, V ;
Gunji, Y ;
Klefstrom, J ;
Kivinen, L ;
Laiho, M ;
Olofsson, B ;
Joukov, V ;
Eriksson, U ;
Alitalo, K .
ONCOGENE, 1997, 14 (20) :2475-2483
[7]
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442
[8]
Angiogenesis as a therapeutic target [J].
Ferrara, N ;
Kerbel, RS .
NATURE, 2005, 438 (7070) :967-974
[9]
Opinion - Angiogenesis: an organizing principle for drug discovery? [J].
Folkman, Judah .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (04) :273-286
[10]
ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM [J].
FONG, GH ;
ROSSANT, J ;
GERTSENSTEIN, M ;
BREITMAN, ML .
NATURE, 1995, 376 (6535) :66-70